SCHEMBL64600

SCHEMBL64600

O=C(NCc1ccc(F)cc1)c1nc2n(c(=O)c1O)CC1CCC2(NS(=O)(=O)c2ccccc2OC(F)(F)F)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.43
CYP2C9 P11712 1/20 0.40
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
KCNE1 P15382 1/20 0.36
CCR1 P32246 1/20 0.36
KCNQ1 P51787 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
LMNA P02545 2/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ERCC1 P07992 1/20 0.35
FEN1 P39748 1/20 0.35
ERCC4 Q92889 1/20 0.35
DCTPP1 Q9H773 1/20 0.34
CALCA P06881 1/20 0.33
NAMPT P43490 1/20 0.33
OPRL1 P41146 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL63575 0.87 KCNH2 (0.47) KCNH2CYP2C9MEN1KMT2AKCNE1
SCHEMBL52509 0.84 KCNH2 (0.49) KCNH2CYP2C9MEN1KMT2AKCNE1
SCHEMBL52328 0.83 KCNH2 (0.51) KCNH2CYP2C9MEN1KMT2AKCNE1
SCHEMBL53061 0.83 KCNH2 (0.57) KCNH2CYP2C9MEN1KMT2AKCNE1
SCHEMBL62804 0.82 KCNH2 (0.45) KCNH2CYP2C9MEN1KMT2AKCNE1
SCHEMBL64598 0.81 KCNH2 (0.46) KCNH2CYP2C9MEN1KMT2AKCNE1
SCHEMBL52562 0.81 KCNH2 (0.45) KCNH2CYP2C9MEN1KMT2AKCNE1
SCHEMBL52342 0.80 KCNH2 (0.50) KCNH2CYP2C9MEN1KMT2AKCNE1
SCHEMBL64050 0.80 KCNH2 (0.46) KCNH2CYP2C9MEN1KMT2AKCNE1
SCHEMBL63875 0.80 KCNH2 (0.45) KCNH2CYP2C9MEN1KMT2AKCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280981-B1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-04-23 EP disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG KCNH2 3969/4885CYP2C9 602/4885MEN1 4650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.